Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
Celltrion's Truxima has 30% market share in Britain
By Catherine ChungPublished : Aug. 1, 2017 - 14:26
An affiliate of South Korean biopharmaceutical firm Celltrion Inc. said Tuesday that its biosimilar drug Truxima accounts for 30 percent of the Britain market.
Truxima, a reference to Roche's Mabthera, also known as Rituxan, has become a presence in the European country since its launch in April, Celltrion Healthcare said.
Truxima, a reference to Roche's Mabthera, also known as Rituxan, has become a presence in the European country since its launch in April, Celltrion Healthcare said.
In February, the European Medicines Agency accepted Celltrion's application to sell the antibody biosimilar which is used in the treatment of a number of diseases, including rheumatoid arthritis and non-Hodgkin's lymphoma, a type of leukemia.
The drug is sold in Britain at a 30 and 40 percent discount to the current list price of Rituxan, the company said.
Biosimilars are officially approved copycat medicines developed after patents for the original biopharmaceuticals expire. (Yonhap)
